Stock 4536 SANTEN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Santen Pharmaceutical Co., Ltd.

Equities

4536

JP3336000009

Delayed Japan Exchange
Other stock markets
 10:30:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
1,630 JPY +0.62% Intraday chart for Santen Pharmaceutical Co., Ltd. -0.55% +16.01%
May. 10 Santen Pharmaceutical Intends to Buy Back and Cancel up to 38 Billion Yen Worth of Shares MT
May. 09 Santen Pharmaceutical Co., Ltd. announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million. CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SANTEN PHARMACEUTICAL CO., LTD. Stock Santen Pharmaceutical Co., Ltd.
+16.01% 3.69B
B+
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+48.39% 765B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.13% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.61% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.00% 299B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.87% 248B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-1.96% 219B
A+
NOVARTIS AG Stock Novartis AG
+11.11% 216B
B-
AMGEN INC. Stock Amgen Inc.
+5.80% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.50% 162B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4536 Stock
  4. Ratings Santen Pharmaceutical Co., Ltd.